Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
Location: United States, Connecticut, New Haven
Employees: 11-50
Total raised: $129.5M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Omega Fund... | omegafunds... |
| - | Aperture V... | aperturevp... |
| - | TPG | tpg.com |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 15.10.2021 | - | $3M | New Enterp... |
| 21.07.2017 | Series C | $50.5M | New Enterp... |
| 08.01.2015 | - | $15M | - |
| 06.11.2014 | Series B | $26M | - |
| 04.06.2014 | Series B | $25M | - |
| 18.12.2012 | Series A | $10M | - |
Mentions in press and media 26
| Date | Title | Description | Source |
| 09.04.2024 | Trevi Therapeutics Announces Abstract Presentation at the Am... | Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in pa... | salamancap... |
| 20.03.2024 | Trevi Therapeutics Reports Fourth Quarter and Year End 2023 ... | Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expecte... | salamancap... |
| 14.07.2022 | Traders News Source Senior Editor Mark Roberts Interviews Je... | NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity resear... | accesswire... |
| 05.01.2022 | Trevi Therapeutics Announces Clinical Trial Updates for Lead... | NEW HAVEN, Conn., Jan. 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical... | marketscre... |
| 11.11.2021 | Trevi Therapeutics Announces Third Quarter 2021 Financial Re... | NEW HAVEN, Conn., Nov. 10, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-... | marketscre... |
| 15.10.2021 | Trevi Therapeutics, Inc. announced that it expects to receiv... | Trevi Therapeutics, Inc. announced that it has entered into a securities purchase agreement with exi... | marketscre... |
| 01.10.2021 | Trevi Therapeutics : Announces $11.8 Million Private Placeme... | NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical... | marketscre... |
| 12.08.2021 | Trevi Therapeutics Announces Second Quarter 2021 Financial R... | prnewswire... | |
| 12.08.2021 | Trevi Therapeutics : Announces Second Quarter 2021 Financial... | NEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-... | marketscre... |
| 09.08.2021 | Trevi Therapeutics : Announces Additions to the Senior Leade... | NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-s... | marketscre... |
Show more